



FOR IMMEDIATE RELEASE

October 29th, 2021

Anwita Biosciences, Inc. Announces Initiation of first-in-human Phase 1 clinical trial of Exenokine-21 for monotherapy and combination, earns \$2.5 million milestone for IND acceptance from Partner Shanghai Junshi Biosciences

SAN CARLOS, California, October 29, 2021 – Anwita Biosciences, Inc. (“Anwita”), a clinical-stage biopharmaceutical company developing proprietary optimized cytokines and antibody drug conjugates, announced today the U.S. Food and Drug Administration (FDA) has accepted company’s Investigational New Drug (IND) application of JS014, an Exenokine-21 molecule designed to extend the half-life of Interleukine-21. The IND application was also cleared by China National Medical Products Administration (NMPA) earlier in the year.

The Phase I open label trial will evaluate the safety and potential response, as well as pharmacokinetics, pharmacodynamics, and immunogenicity of JS014 as a single agent and in combination with a flat dose of pembrolizumab in approximately 60 patients with advanced cancers who have failed standard therapy. The results from Phase I studies will provide recommended Phase II dose to further explore the antitumor activities of JS014 in future clinical studies.

“The FDA’s clearance of our IND for Phase I clinical trial of JS014 in cancer patients marks a significant step towards validating our approach. Our clinical trial aims to reproduce encouraging nonclinical results that demonstrated safety and potent antitumor activity of JS014 in multiple tumor models. We are excited to follow the progress and the development of JS014 in the upcoming Phase I trials, and in the continuing collaboration with Shanghai Junshi Biosciences” said Ziyang Zhong, President & CEO of Anwita Biosciences, Inc.

With the successful IND filing to the China NMPA, Anwita earned \$2.5 million milestone payment from Shanghai Junshi Biosciences who licensed Greater China Rights for Exenokine-21.

About Anwita Biosciences, Inc.

Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and

development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.

Investor Relations

Contact: Investor Relations

Telephone: (650) 600-9828

Email: contact@anwitabio.com

Website: www.anwitabio.com